BIIB 250509 125.00P(BIIB250509P125000) Stock Price Today | Quotes & News - Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

US OptionsDetailed Quotes

BIIB250509P125000

Watchlist

7.10
0.000.00%

15min DelayTrading Apr 30 14:43 ET

0.00High0.00Low

Intraday

5D
Daily

News

Biogen Is Maintained at Outperform by Mizuho
Dow Jones09:26 ET · Ratings
Biogen Price Target Cut to $169.00/Share From $207.00 by Mizuho
Dow Jones09:26 ET · Ratings
Biogen Analyst Ratings
Benzinga09:14 ET · Ratings
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $169
Moomoo News20:31 ET · Ratings
Mizuho Securities Remains a Buy on Biogen (BIIB)
TipRanks14:15 ET · Ratings
Mizuho Cuts Price Target on Biogen to $169 From $207
MT Newswires14:06 ET · Ratings

Comments

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

$Biogen (BIIB.US)$
Breakthrough: First-Ever Drug to Slow Early Alzheimer's Gets EU Green Light

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

1

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

$Organon & Co (OGN.US)$ $Biogen (BIIB.US)$
Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

$Biogen (BIIB.US)$
Biogen's Bold Move: 580,000 sq ft Innovation Powerhouse to Transform Kendall Square Research Hub

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

$Biogen (BIIB.US)$
Biogen's Breakthrough Drug Enters Final Testing Phase for Critical Kidney Transplant Complication

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

confirmed bottom

$Biogen (BIIB.US)$ confirmed technical bottom

Read more